Strathspey Crown Holdings subsidiary and social commerce firm Alphaeon has completed the acquisition of US-based commercial stage medical device firm, Lensar, for an undisclosed amount.
Established in 2004, Lensar is a developer and manufacturer of femtosecond laser systems (FLS) through a wholly owned subsidiary.
At the signing of the agreement in November, Alphaeon noted the transaction is valued at up to $59m in cash, stock and assumed debt.
The company developed the femtosecond cataract laser to enable automation of critical surgical procedure planning.
The Lensar laser system provides patients with better outcomes following the removal of their crystalline lens.
Alphaeon CEO Robert Grant said: "We are pleased to have closed the acquisition of Lensar.
"The advancements they have made in the self-pay category of precision refractive surgery complement our lifestyle product portfolio, allowing ophthalmologists to offer another alternative to patients."
The acquisition allows Alphaeon to expand its ophthalmology business, offering advanced technology to its network of more than 4,200 board certified ophthalmologists worldwide.
Last December, Alphaeon also acquired Canada-based Clarion Medical Technologies for $55m.
Established in 1989, Clarion supplies medical and aesthetic equipment and consumables for hospitals and private practices in Canada. Formerly known as Coherent-AMT, Clarion has 100 employees, 36 sales representatives and more than 40 product licenses.
Alphaeon is a lifestyle healthcare firm that works with board certified physicians to provide new products and services.
Strathspey Crown is an equity firm specialising in lifestyle healthcare and its investors include board certified physician specialists across key medical specialties, comprising plastic surgery, ophthalmology, dermatology, dentistry and orthopaedics.
Image: Alphaeon Corporation in Irvine, California. Photo: courtesy of Alphaeon.